4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following update on Thetanix, its proprietary programme for the treatment of Paediatric Crohn's Disease.

The Company previously reported a precautionary delay in dosing of patients in the Thetanix phase 1 clinical trial, due to quality concerns that had come to light at one of the Company's supply partners during manufacture of an additional batch of Thetanix. The Company is now pleased to report that its investigation into the matter has been completed and that the MHRA has given its approval for the clinical study to be restarted.